Processa Pharmaceuticals Stock EBITDA
| PCSA Stock | USD 0.98 0.04 3.92% |
Processa Pharmaceuticals fundamentals help investors to digest information that contributes to Processa Pharmaceuticals' financial success or failures. It also enables traders to predict the movement of Processa Stock. The fundamental analysis module provides a way to measure Processa Pharmaceuticals' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Processa Pharmaceuticals stock.
| Last Reported | Projected for Next Year | ||
| EBITDA | -11.5 M | -10.9 M |
Processa | EBITDA |
Processa Pharmaceuticals Company EBITDA Analysis
Processa Pharmaceuticals' EBITDA stands for earnings before interest, taxes, depreciation, and amortization. It is a measure of a company operating cash flow based on data from the company income statement and is a very good way to compare companies within industries or across different sectors. However, unlike Operating Cash Flow, EBITDA does not include the effects of changes in working capital.
Current Processa Pharmaceuticals EBITDA | (11.46 M) |
Most of Processa Pharmaceuticals' fundamental indicators, such as EBITDA, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Processa Pharmaceuticals is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Processa EBITDA Driver Correlations
Understanding the fundamental principles of building solid financial models for Processa Pharmaceuticals is extremely important. It helps to project a fair market value of Processa Stock properly, considering its historical fundamentals such as EBITDA. Since Processa Pharmaceuticals' main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Processa Pharmaceuticals' historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Processa Pharmaceuticals' interrelated accounts and indicators.
Click cells to compare fundamentals
In a nutshell, EBITDA is calculated by adding back each of the excluded items to the post-tax profit, and can be used to compare companies with very different capital structures.
| Competition |
Processa Ebitda
Ebitda |
|
According to the company disclosure, Processa Pharmaceuticals reported earnings before interest,tax, depreciation and amortization of (11.46 Million). This is 101.31% lower than that of the Biotechnology sector and 111.44% lower than that of the Health Care industry. The ebitda for all United States stocks is 100.29% higher than that of the company.
Processa EBITDA Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Processa Pharmaceuticals' direct or indirect competition against its EBITDA to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Processa Pharmaceuticals could also be used in its relative valuation, which is a method of valuing Processa Pharmaceuticals by comparing valuation metrics of similar companies.Processa Pharmaceuticals is currently under evaluation in ebitda category among its peers.
Processa Pharmaceuticals Institutional Holders
Institutional Holdings refers to the ownership stake in Processa Pharmaceuticals that is held by large financial organizations, pension funds or endowments. Institutions may purchase large blocks of Processa Pharmaceuticals' outstanding shares and can exert considerable influence upon its management. Institutional holders may also work to push the share price higher once they own the stock. Extensive social media coverage, TV shows, articles in high-profile magazines, and presentations at investor conferences help move the stock higher, increasing Processa Pharmaceuticals' value.| Shares | Citadel Advisors Llc | 2024-06-30 | 0.0 | Two Sigma Investments Llc | 2024-06-30 | 0.0 | Vanguard Group Inc | 2024-09-30 | 24.4 K | Geode Capital Management, Llc | 2024-09-30 | 19.7 K | Tower Research Capital Llc | 2024-06-30 | 3 K | Wells Fargo & Co | 2024-06-30 | 154 | Main Street Group Ltd | 2024-06-30 | 100.0 | Hanson Mcclain Inc | 2024-09-30 | 85.0 | Bank Of America Corp | 2024-06-30 | 21.0 | Royal Bank Of Canada | 2024-06-30 | 4.0 | Absolute Investment Management Llc | 2024-09-30 | 1.0 |
Processa Fundamentals
| Return On Equity | -2.12 | ||||
| Return On Asset | -1.13 | ||||
| Current Valuation | 407.31 K | ||||
| Shares Outstanding | 3.27 M | ||||
| Shares Owned By Insiders | 8.74 % | ||||
| Shares Owned By Institutions | 1.48 % | ||||
| Number Of Shares Shorted | 73.06 K | ||||
| Price To Book | 0.86 X | ||||
| EBITDA | (11.46 M) | ||||
| Net Income | (11.12 M) | ||||
| Cash And Equivalents | 12.06 M | ||||
| Cash Per Share | 0.76 X | ||||
| Total Debt | 150.55 K | ||||
| Debt To Equity | 0 % | ||||
| Current Ratio | 8.89 X | ||||
| Book Value Per Share | 1.14 X | ||||
| Cash Flow From Operations | (8.06 M) | ||||
| Short Ratio | 2.42 X | ||||
| Earnings Per Share | (4.80) X | ||||
| Price To Earnings To Growth | (0.12) X | ||||
| Target Price | 6.0 | ||||
| Number Of Employees | 13 | ||||
| Beta | 0.6 | ||||
| Market Capitalization | 3.2 M | ||||
| Total Asset | 5.79 M | ||||
| Retained Earnings | (75.37 M) | ||||
| Working Capital | 4.9 M | ||||
| Net Asset | 5.79 M |
About Processa Pharmaceuticals Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Processa Pharmaceuticals's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Processa Pharmaceuticals using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Processa Pharmaceuticals based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether Processa Pharmaceuticals offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Processa Pharmaceuticals' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Processa Pharmaceuticals Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Processa Pharmaceuticals Stock:Check out Processa Pharmaceuticals Piotroski F Score and Processa Pharmaceuticals Altman Z Score analysis. For information on how to trade Processa Stock refer to our How to Trade Processa Stock guide.You can also try the Economic Indicators module to top statistical indicators that provide insights into how an economy is performing.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Processa Pharmaceuticals. If investors know Processa will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Processa Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (4.80) | Return On Assets (1.13) | Return On Equity (2.12) |
The market value of Processa Pharmaceuticals is measured differently than its book value, which is the value of Processa that is recorded on the company's balance sheet. Investors also form their own opinion of Processa Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Processa Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Processa Pharmaceuticals' market value can be influenced by many factors that don't directly affect Processa Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Processa Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Processa Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Processa Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.